EU Medical Devices Regulation – Unique Device Identifier (UDI)
In 2017, two Regulations on medical devices (MDR) and in in vitro diagnostic medical devices (IVDR) entered into force in the European Union (EU), establishing a modernized and more robust EU legislative framework and safeguarding a better public health protection and patient safety. According to the these Regulations, the Unique Device Identifier (UDI) will be mandatory for all medical devices and in vitro medical devices.
Liliana Teles

Liliana Teles

Regulatory Affairs Manager

MDR, IVDR and UNIQUE DEVICE IDENTIFIER (UDI)

According to the new EU Medical Devices Regulation (MDR – Regulation (EU) 2017/745) and the In Vitro Diagnostic Medical Devices Regulation  (IVDR – Regulation (EU) 2017/746), the “Unique Device Identifier” (UDI) means a “series of numeric or alphanumeric characters that is created through internationally accepted device identification and coding standards and that allows unambiguous identification of specific devices on the market”.

The main goal of the UDI is to allow the identification and improve the traceability of devices. The UDI will also allow a better monitoring by the competent authorities as well as it represents a fighting mechanism against counterfeit medical devices.

The UDI will be mandatory for all medical devices and in vitro medical devices, except for the custom-made and performance study/investigational devices.

The UDI system is described in the Part C of Annex VI of both Regulations and consists of several parts:Production of an UDI:

  • UDI device identifier (‘UDI-DI’), which is specific to a manufacturer and a device;
  • UDI production identifier (‘UDI-PI’), which identifies the unit device production and the package devices (if applicable).
  • Placing the UDI on the label of the device or its packaging (specific requirements);
  • Storage of the UDI by economic operators, health institutions and health care professionals;
  • Establishment of an electronic system for Unique Device Identification (‘UDI database’).

The basic UDI-DI will be the access key for device-related information and therefore is referenced in relevant documentation (e.g., certificates, declaration of conformity, technical documentation). The basic UDI-DI has the objective of identifying (in a unique manner) and connect devices with the same intended purpose.

The label and all higher levels of packaging (not shipping containers) of medical devices must include the UDI information, including the UDI-DI and UDI-PI. In case of reusable devices, the UDI carrier shall be placed on the device itself (direct marking). The UDI-DI of the device should appear on the EU declaration of conformity.

An UDI shall be attributed to a medical device created before placing such device on the market. The manufacturer should ensure that all information required is correctly submitted to the UDI database (European Database on Medical Devices – EUDAMED). Moreover, the manufacture needs to keep up-to-date a list of all UDIs that is has assigned.

The UDI database, integrated with EUDAMED, should be set up and managed by the European Commission, in order to validate, collate, process and make available the information to the public (free of charge, with maximum accessibility).

UDI OBLIGATIONS TIMELINE

The UDI assignment will be mandatory from 26th May 2021 for medical devices and from 26th May 2022 for in vitro diagnostic medical devices. When it comes to the submission of UDI data at EUDAMED database, it will be obligatory for medical devices from 26th November 2022 and from 26th November 2023 for in vitro diagnostic medical devices. Manufacturers may voluntarily comply with registration of their medical devices and in vitro medical devices from 26th May 2021 and 26th May 2022, respectively.

When it comes to the obligation of placing the UDI carrier, the timeline will be in accordance with the type of medical device (risk-based). UDI-carriers must be placed on the labels of class III devices by 26 May 2021 as long as for class I devices the timeline is 26 May 2025.

In sum, the manufacturer has the responsibility of assigning and register the UDI (and basic UDI-DI) and placing that information on the label and/or packaging. If a distributor, importer or other natural or legal person assumes the obligations incumbent on manufacturers, it also assumes all relevant responsibilities related to UDI (including labelling).

The UDI system can be complex and medical devices manufacturers must ensure compliance with the MDR and IVDR. Our team is here to assist your company throughout the entire process, turning it simpler and easier to make your medical device available on the EU market.

References:

  1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices. Available at: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:02017R0745-20200424&from=EN
  2. Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices. Available at: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:02017R0746-20170505&from=EN
  3. MDCG 2019-4 . Timelines for registration of device data elements in EUDAMED. Available at: https://ec.europa.eu/docsroom/documents/34921

further
reading

drug_device_combination_1
medical devices

Regulatory Framework of Drug-Device Combination

The advances in technology continue to merge different types of products and the historical lines of separation between medical devices and medicinal products are getting thinner. Products combining medicinal products and medical devices are regulated either by Regulation (EU) 2017/745 (MDR) or by Directive 2001/83/EC.

Read More »
cosmetic products

SCCS Preliminary Opinion on Alpha-Arbutin and Beta-Arbutin

Alpha-arbutin and Beta-arbutin are used in cosmetic with antioxidant, bleaching and skin conditioning functions. Following concerns raised during discussion within the Working Group on Cosmetic Products and consequent call for data on these ingredients, the SCCS assessed the safety of Alpha-arbutin and Beta-arbutin in cosmetic products.

Read More »
cosmetic products

Request for SCCS Scientific Opinion on Citral

The European Commission requested the SCCS to assess whether the derived safe use levels for Citral by the application of the QRA2 based on the induction of skin sensitization is adequate to protect consumers. A period of 9 months was set for issuing the scientific opinion.

Read More »
cosmetic products

SCCS Scientific Advice on the Safety of Triclocarban and Triclosan

The European Commission Scientific Committee on Consumer Safety (SCCS) has published its preliminary version of the scientific advice on the safety of Triclocarban and Triclosan as substances with potential endocrine disrupting properties in cosmetic products. The deadline for comments was set at 27 May 2022.

Read More »
cosmetic products

Cosmetic Regulation in the Andean Community

In the Andean Community (Bolivia, Colombia, Ecuador and Peru), cosmetic products are mainly regulated by Decision 833. All cosmetic products made available in these countries must undergo a Mandatory Sanitary Notification (NSO) and need to be manufactured according to Good Manufacturing Practices (GMP).

Read More »
cosmetic products

Cosmetic Product Labelling in the European Union

The Regulation (EC) No 1223/2009 lays down the mandatory information that needs to be included in the packaging and container of a cosmetic products. In addition to this information, most cosmetic products include certain claims, which must be supported and properly substantiated.

Read More »
cosmetic products

Environmental Claims in the UK

Green claims are a trend among consumer goods and services. We often see claims like ‘clean beauty’, ‘environmental friendly’ and so many others. But how can companies ensure that these claims are not misleading? The UK’s Competition and Markets Authority (CMA) has published its Green Claims Code, in order to help companies comply with legal obligations when making environmental claims.

Read More »
cosmetic products

Parabens in Cosmetic Products

Parabens are widely used as preservatives in cosmetic and personal care products. Over the years, there have been some concerns related to the safety of parabens. The SCCS has published several opinions regarding the use of these ingredients in cosmetics, indicating the concentration levels they considered safe for human health. In the EU, some parabens can be safely used as preservatives, while others are prohibited in cosmetic products.

Read More »
cosmetic products

The Product Information File (PIF)

A Product Information File (PIF) is mandatory for all cosmetic products placed in the European Union market. It is a document that compiles the technical information of the cosmetic product and it must be kept for a period of 10 years by the Responsible Person.

Read More »
cosmetic products

How are Cosmetic Products Regulated in Australia?

The Australian Industrial Chemicals Introduction Scheme (AICIS) is the entity responsible for controlling cosmetics and soaps. Cosmetic ingredients are regulated as industrial chemicals under the Industrial Chemicals Act 2019, which is administered by AICIS.

Read More »